



MEN

FIRST CANCER SITE  
TESTISTESTIS  
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

TESTICOLO  
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	7739		7954		7954		7739		6951		4234		2115		7739	7954
Person-years ▶	54475		55782		1307		6115		21837		15544		10979		54475	55782
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND TESTIS	246	1.24	256	1.27	10	3.21	27	1.88	61	1.05	65	1.16	93	1.33	0.87	0.98
HEAD AND NECK	13	1.08	13	1.07	0	0.00	1	1.18	2	0.56	5	1.43	5	1.22	0.02	0.01
ORAL CAVITY	4	1.23	4	1.21	0	0.00	0	0.00	0	0.00	2	2.09	2	1.81	0.01	0.01
PHARYNX	4	1.24	4	1.22	0	0.00	0	0.00	0	0.00	2	2.10	2	1.80	0.01	0.01
LARYNX	5	0.90	5	0.89	0	0.00	1	2.50	2	1.20	1	0.63	1	0.53	-0.01	-0.01
OESOPHAGUS	2	0.84	2	0.82	0	0.00	0	0.00	0	0.00	1	1.46	1	1.18	-0.01	-0.01
STOMACH	14	1.38	14	1.35	0	0.00	1	1.24	2	0.63	3	1.05	8	2.41	0.07	0.07
COLON RECTUM	30	1.19	30	1.17	0	0.00	4	2.33	7	0.98	10	1.41	9	0.97	0.09	0.08
COLON	26	1.55	26	1.53	0	0.00	3	2.65	7	1.49	8	1.71	8	1.28	0.17	0.16
RECTUM	4	0.47	4	0.47	0	0.00	1	1.71	0	0.00	2	0.83	1	0.33	-0.08	-0.08
LIVER	9	1.22	9	1.20	0	0.00	0	0.00	3	1.45	1	0.48	5	1.81	0.03	0.03
GALLBLADDER	4	2.50	4	2.46	0	0.00	0	0.00	0	0.00	2	4.51	2	3.53	0.04	0.04
PANCREAS	6	1.20	6	1.18	0	0.00	0	0.00	0	0.00	3	2.13	3	1.64	0.02	0.02
LUNG	27	0.90	29	0.95	2	4.21	4	1.84	7	0.79	7	0.83	9	0.85	-0.06	-0.03
SKIN MELANOMA	11	1.59	11	1.57	0	0.00	1	1.81	2	0.88	4	1.96	4	1.95	0.08	0.07
MESOTHELIOMA	1	0.96	1	0.95	0	0.00	0	0.00	0	0.00	0	0.00	1	2.46	0.00	0.00
KAPOSI SARCOMA	2	2.16	2	2.12	0	0.00	0	0.00	1	2.91	1	3.65	0	0.00	0.02	0.02
SOFT TISSUE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
BONE	1	2.03	1	1.99	0	0.00	0	0.00	0	0.00	1	7.35	0	0.00	0.01	0.01
BREAST	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
PROSTATE	29	1.02	30	1.04	1	2.67	1	0.59	8	1.14	9	1.19	11	0.90	0.01	0.02
TESTIS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.09	-0.09
KIDNEY AND RENAL PELVIS	12	1.48	15	1.83	3	25.65	1	1.82	3	1.28	3	1.28	5	1.75	0.07	0.12
BLADDER AND URINARY TRACT	26	1.33	26	1.31	0	0.00	2	1.43	6	1.05	3	0.55	15	2.16	0.12	0.11
URINARY BLADDER	26	1.39	26	1.36	0	0.00	2	1.49	6	1.10	3	0.57	15	2.25	0.13	0.12
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BRAIN AND CENTRAL NERVOUS SYSTEM	6	1.42	6	1.39	0	0.00	0	0.00	2	1.41	2	1.63	2	1.62	0.03	0.03
THYROID	10	2.88	11	3.11	1	15.90	1	3.33	4	3.36	2	1.94	3	3.16	0.12	0.13
HODGKIN LYMPHOMA	3	1.29	4	1.68	1	16.55	2	7.10	0	0.00	0	0.00	1	2.38	0.01	0.03
NON-HODGKIN LYMPHOMA	13	1.45	13	1.42	0	0.00	6	8.29	3	1.03	3	1.15	1	0.36	0.07	0.07
MYELOMA	1	0.41	3	1.21	2	53.14	0	0.00	0	0.00	0	0.00	1	1.15	-0.03	0.01
LEUKAEMIAS	14	2.64	14	2.59	0	0.00	3	6.71	4	2.32	4	2.66	3	1.85	0.16	0.15
LYMPHOID LEUKAEMIAS	6	2.42	6	2.38	0	0.00	3	15.13	0	0.00	2	2.84	1	1.26	0.06	0.06
MYELOID LEUKAEMIAS	7	2.76	7	2.71	0	0.00	0	0.00	4	4.73	2	2.78	1	1.33	0.08	0.08
OTHER LEUKAEMIAS	1	3.44	1	3.37	0	0.00	0	0.00	0	0.00	0	0.00	1	12.53	0.01	0.01
OTHER AND ILL DEFINED SITES	12	1.15	12	1.13	0	0.00	0	0.00	7	2.14	1	0.34	4	1.18	0.03	0.02

Decrease/Difetto  
Increase/Eccesso

O Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio